RayKnowChina Research Map
Shortlist

Shenzhen

The University of Hong Kong–Shenzhen Hospital

香港大学深圳医院

Listed for 14 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at The University of Hong Kong–Shenzhen Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌26 papers led1 open trial led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led
  3. Hepatocellular carcinoma肝细胞癌40 papers led
  4. Hepatoblastoma肝母细胞瘤1 paper led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Neuroblastoma神经母细胞瘤1 paper led
  7. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  8. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  9. Spinal muscular atrophy脊髓性肌萎缩症1 paper led
  10. Fabry disease法布雷病0 papers led
  11. Behçet disease白塞病0 papers led
  12. Osteogenesis imperfecta成骨不全症6 papers led
  13. Hirschsprung disease先天性巨结肠1 paper led
  14. Hereditary angioedema遗传性血管性水肿2 papers led

Not listed for: Stomach cancer, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 26 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
26
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 6620222023: 5520232024: 4420242025: 662025

8 hospitals in Shenzhen for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07013461

    Age 18 years to Not stated (registered criteria)

    Led by The University of Hong Kong–Shenzhen HospitalShenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersMedical oncologyENT / head & neck surgery
Papers it led26
  1. C1q+ Macrophage-Tumor Cell Interaction Promoted Tumorigenesis via GPR17/PI3K/AKT Pathway Induced DNA Hypermethylation in Nasopharyngeal Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. SOX4-ZIP14-zinc metabolism mediates oncogenesis and suppresses T cell immunity in nasopharyngeal carcinoma.2025Cell reports. MedicineFree full text
  3. Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation.2025Cellular & molecular immunologyFree full text
  4. Tertiary lymphoid structure-related RNA indicator as metastasis risk factor in nasopharyngeal carcinoma.2025Clinical and translational medicineFree full text
  5. International Consensus Guideline on Delineation of the Clinical Target Volumes at Different Dose Levels for Nasopharyngeal Carcinoma (2024 Version).2025International journal of radiation oncology, biology, physics
  6. Virus-human chromatin interactions reorganise 3D genome and hijack KDM5B for promoting metastasis in nasopharyngeal carcinoma.2025Nature communicationsFree full text
  7. Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma.2024Cancer treatment reviews
  8. International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal Carcinoma.2024International journal of radiation oncology, biology, physics
  9. ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent nasopharyngeal carcinoma.2024Journal of advanced researchFree full text
  10. Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  11. Treatment strategy for de novo metastatic nasopharyngeal carcinoma: a literature review.2023Chinese clinical oncology
  12. Management of the neck in nasopharyngeal carcinoma-time for a radical change?2023Chinese clinical oncology
  13. Small Changes, Big Impact: Excitement and Caution in Dose and Volume Reduction for Nasopharyngeal Carcinoma Radiation Therapy After Induction Chemotherapy.2023International journal of radiation oncology, biology, physics
  14. Hyperfractionation for reirradiation of recurrent nasopharyngeal carcinoma.2023Lancet (London, England)
  15. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction.2023Nature communicationsFree full text
  16. Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.2022Clinical cancer research : an official journal of the American Association for Cancer Research
  17. The Janus Face in Defining the Optimal Radiation Dose for Nasopharyngeal Carcinoma.2022International journal of radiation oncology, biology, physics
  18. Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box?2022JAMA oncology
  19. Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?2022Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  20. Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.2022Oral oncology
  21. International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.2022The Lancet. OncologyFree full text
  22. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma.2021European journal of cancer (Oxford, England : 1990)
  23. Locoregional Radiation Therapy for De Novo Metastatic Nasopharyngeal Cancer: One Size Fits All?2021International journal of radiation oncology, biology, physics
  24. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma.2021Nature communicationsFree full text
  25. Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasophar2021Oral oncology
  26. Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma.2021The Lancet. Oncology
Chinese-language papers (not in the count)1
  1. [Extracranial/intracranial vascular bypass to control carotid artery blowout in postirradiated nasopharyngeal carcinoma patients].2021Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
All its trials on ClinicalTrials.gov, any status3
  1. International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal CancerRecruitingNCT07013461Lead sponsorStart 2026-01
  2. Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.Active, not recruitingNCT07201337Study sitePhase 3Start 2025-11
  3. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Study sitePhase 3Start 2025-02
More papers found outside PubMed (not counted)10
  1. CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma2025Holistic Integrative Oncologyarticle
  2. Effect of statins on the mortality of long-term survivors of nasopharyngeal carcinoma.2025Journal of Clinical Oncologyarticle
  3. Grad-MTSeg: Mitigating Multi-Task Gradient Conflicts via Hierarchical Gradient Optimization for NPC Radiotherapy Delineation2025IEEE International Conference on Bioinformatics and Biomedicine (BIBM)conference-paper
  4. Data from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma2023Venue not listedother
  5. Data from Clinical Outcome–Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma2023Venue not listedother
  6. m6A Demethylase FTO Regulates Nasopharyngeal Carcinoma Invasion, Migration2023Journal of Genetics and Genome Researcharticle
  7. 666P Circulating CX3CR1+CD8 T and Th17 cells and immunotherapy response in recurrent or metastatic NPC2022Annals of Oncologyarticle
  8. A potential survival impact of blood immune cells in patients with locoregionally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.2021Journal of Clinical Oncologyconference-abstract
  9. Cisplatin and capecitabine induction chemotherapy in nasopharyngeal carcinoma.2021Journal of Clinical Oncologyconference-abstract
  10. Diagnosis and Staging of Nasopharyngeal Cancer2021Practical guides in radiation oncologybook-chapter

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 442025

3 hospitals in Shenzhen for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AI
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led7
  1. Characterizing chromosome instability reveals its association with lipid-associated macrophages and clonal evolution of lymph node metastasis in esophageal squamous cell carcinoma.2025Cancer letters
  2. Anovel anti-B7-H3 nanobody and its DM1 conjugate with marked anti-tumor activity against esophageal squamous cell carcinoma.2025International journal of biological macromolecules
  3. Targeting FTL regulates ferroptosis and remodels lymph node metastasis microenvironment in esophageal squamous cell carcinoma.2025International journal of biological sciencesFree full text
  4. FAO-fueled OXPHOS and NRF2-mediated stress resilience in MICs drive lymph node metastasis.2025Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  5. ImmuneMirror: A machine learning-based integrative pipeline and web server for neoantigen prediction.2024Briefings in bioinformaticsFree full text
  6. GPRC5A promotes lung colonization of esophageal squamous cell carcinoma.2024Nature communicationsFree full text
  7. Targeting MFGE8 secreted by cancer-associated fibroblasts blocks angiogenesis and metastasis in esophageal squamous cell carcinoma.2023Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
More papers found outside PubMed (not counted)5
  1. Abstract 7: Lipid-driven oxidative phosphorylation fuels lymph node colonization by esophageal tumor cells2025Cancer Researchconference-abstract
  2. MO57-3 Effect of immunochemotherapy time-of-day infusion, sequence and interval on prognosis of advanced esophageal cancer2024Annals of Oncologyarticle
  3. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  4. GOLM1 affects proliferation, invasion, and migration by regulating Wnt pathway in esophageal squamous cell carcinoma cells2023Journal of Radiation Research and Applied Sciencesarticle
  5. Induction immunochemotherapy conversion rate and survival outcomes versus chemotherapy in initially unresectable esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 40 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
40
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 9920222023: 7720232024: 101020242025: 882025

8 hospitals in Shenzhen for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesHepatitis B & cirrhosisSurgery & liver transplantImaging, AI & early detection
Departments in papersMedical oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine
Papers it led40
  1. Development and Validation of a Nomogram for Preoperative Prediction of Non-Textbook Outcome in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma Based on Lasso-Logistic Regression.2026ANZ journal of surgery
  2. Compensatory Hypertrophy and Changes of Liver Function After Sequential Transarterial Chemoembolization, Stereotactic Body Radiation Therapy, and Immunotherapy (START-FIT) in Unresectable Hepatocellular Carcinoma.2026International journal of radiation oncology, biology, physics
  3. Analysis of risk factors for early mortality following hepatectomy in hepatocellular carcinoma patients.2025BMC surgeryFree full text
  4. Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production.2025Cell reports. MedicineFree full text
  5. Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B.2025Clinical and molecular hepatologyFree full text
  6. DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC.2025Hepatology (Baltimore, Md.)
  7. Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery.2025Hepatology (Baltimore, Md.)
  8. Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance.2025Hepatology communicationsFree full text
  9. Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.2025Journal of hepatology
  10. Opportunistic Detection of Hepatocellular Carcinoma Using Noncontrast CT and Deep Learning Artificial Intelligence.2025Journal of the American College of Radiology : JACR
  11. Loss of ESRP2 Activates TAK1-MAPK Signaling through the Fetal RNA-Splicing Program to Promote Hepatocellular Carcinoma Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  12. Unveiling KLHL23 as a key immune regulator in hepatocellular carcinoma through integrated analysis.2024AgingFree full text
  13. Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetes.2024Alimentary pharmacology & therapeutics
  14. FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma.2024Cancer research
  15. Extracellular vesicles and cancer stemness in hepatocellular carcinoma - is there a link?2024Frontiers in immunologyFree full text
  16. Enhanced mitophagy driven by ADAR1-GLI1 editing supports the self-renewal of cancer stem cells in HCC.2024Hepatology (Baltimore, Md.)
  17. The mechanistic insights behind the anticancer effects of statins in liver cancer.2024Hepatology communicationsFree full text
  18. The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects.2024Hepatology communicationsFree full text
  19. Cell cycle inhibitors activate the hypoxia-induced DDX41/STING pathway to mediate antitumor immune response in liver cancer.2024JCI insightFree full text
  20. Comparison of the Ability of Gadobenate Dimeglumine and Gadolinium Ethoxybenzyl Dimeglumine to Display the major Features for Noninvasively Diagnosing Hepatocellular Carcinoma According to the LI-RADS 2018v.2024Technology in cancer research & treatmentFree full text
  21. Protein Tyrosine Kinase 7 (PTK7) Promotes Metastasis in Hepatocellular Carcinoma via SOX9 Regulation and TGF-β Signaling.2023Cellular and molecular gastroenterology and hepatologyFree full text
  22. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.2023Hepatology (Baltimore, Md.)
  23. SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling.2023Hepatology (Baltimore, Md.)
  24. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis.2023Hepatology (Baltimore, Md.)
  25. Genipin-activating PPARγ impedes CCR2-mediated macrophage infiltration into postoperative liver to suppress recurrence of hepatocellular carcinoma.2023International journal of biological sciencesFree full text
  26. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.2023Journal of experimental & clinical cancer research : CRFree full text
  27. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial2023The lancet. Gastroenterology & hepatology
  28. GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.2022Cancer gene therapy
  29. Enhanced Liver Fibrosis Score Stratifies Hepatocellular Carcinoma Risk in Patients With Hepatitis B Surface Antigen Seroclearance.2022Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  30. Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression.2022Gut
  31. Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma.2022Hepatology international
  32. Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation.2022International journal of molecular sciencesFree full text
  33. Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma.2022Journal of experimental & clinical cancer research : CRFree full text
  34. Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B.2022Journal of gastroenterology and hepatology
  35. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.2022Journal of hematology & oncologyFree full text
  36. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.2022MedicineFree full text
  37. Efficacy and safety of radiotherapy for primary liver cancer.2021Chinese clinical oncology
  38. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.2021Hepatology international
  39. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance.2021Hepatology international
  40. C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism.2021OncogeneFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Shenzhen for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

20 hospitals in Shenzhen for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

10 hospitals in Shenzhen for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Shenzhen for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Shenzhen for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led1
  1. Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis?2022American journal of respiratory and critical care medicine
All its trials on ClinicalTrials.gov, any status2
  1. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  2. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shenzhen for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Shenzhen for Fabry disease80 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Zebra Bodies in the Kidney.2020The New England journal of medicine
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Shenzhen for Behçet disease139 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 6 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 6.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 222025

4 hospitals in Shenzhen for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07557446

    Age 12 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Changsha, Shanghai, Shenzhen, Suzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led6
  1. Lower limb deformity and gait deviations of osteogenesis imperfecta.2025Gait & posture
  2. An inducible mouse model of osteogenesis imperfecta type V reveals aberrant osteogenesis caused by Ifitm5 c.-14C>T mutation.2025Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  3. Multi-omics analyses reveal aberrant differentiation trajectory with WNT1 loss-of-function in type XV osteogenesis imperfecta.2024Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  4. Clinical features and molecular characterization of Chinese patients with FKBP10 variants.2023Molecular genetics & genomic medicine
  5. Retrospective analyses of clinical features in 28 Chinese patients with type V osteogenesis imperfecta: new perspectives in an old issue.2023Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  6. Patient-reported outcomes in a Chinese cohort of osteogenesis imperfecta unveil psycho-physical stratifications associated with clinical manifestations.2022Orphanet journal of rare diseases
All its trials on ClinicalTrials.gov, any status2
  1. A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)RecruitingNCT07557446Study sitePhase 2Start 2026-07
  2. Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaActive, not recruitingNCT05972551Study sitePhase 3Start 2024-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shenzhen for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 2 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 6.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

2 hospitals in Shenzhen for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Hereditary Angioedema (HAE) in China: Advancing Awareness, Access, Advocacy and Alliances From the Greater Bay Area to the Global HAE Community.2025Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  2. The potential of factor XII inhibitors in preventing hereditary angioedema attacks.2025Expert opinion on biological therapy

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

香港大学深圳医院

The University of Hong Kong–Shenzhen Hospital

深圳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
University of Hong Kong-Shenzhen Hospital; and The University of Hong Kong-Shenzhen Hospital; University of Hongkong-Shenzhen Hospital; HKU-Shenzhen Hospital; University of Hongkong- Shenzhen Hospital; Clinical Oncology CentreThe University of Hong Kong-Shenzhen Hospital; University of Hong Kong-Shenzhen Hospital (HKU-SZH); HKU-SZ

Suggest a correctionDownload the data